There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jazz Pharmaceuticals (JAZZ – Research Report) and Legend Biotech (LEGN – Research Report) with bullish sentiments.
Jazz Pharmaceuticals (JAZZ)
BMO Capital analyst Gary Nachman maintained a Buy rating on Jazz Pharmaceuticals today and set a price target of $188.00. The company’s shares closed last Friday at $155.25.
According to TipRanks.com, Nachman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Jazz Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $199.00, which is a 28.0% upside from current levels. In a report issued on January 5, RBC Capital also maintained a Buy rating on the stock with a $203.00 price target.
See the top stocks recommended by analysts >>
Legend Biotech (LEGN)
BMO Capital analyst Kostas Biliouris maintained a Buy rating on Legend Biotech today and set a price target of $79.00. The company’s shares closed last Friday at $54.40, close to its 52-week high of $57.72.
According to TipRanks.com, Biliouris is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Legend Biotech with a $72.67 average price target, representing a 33.0% upside. In a report issued on January 5, Jefferies also maintained a Buy rating on the stock with a $73.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on JAZZ:
- Jazz Pharmaceuticals, Zymeworks report 84% survival for zanidatamab in mGEA
- FDA Contemplates Regulating CBD in Edibles
- Jazz to continue with its rights to Zymeworks’ zanidatamab in key markets
- Zymeworks upgraded to Buy at Jefferies with increased clarity
- Invest like a Pro: These 10 Stocks Could Outperform in 2023
